1Brown S,Reynolds N J. Atopic and non-atopic eczema[J]. BMJ,2006,332(7541):584-588.
2De Benedetto A,Agnihothri R,McGirt L Y,et al. Atopic dermatitis:a disease caused by innate immune defects[J]. J Invest Dermatol,2009,129(1):14-30.
3Steinhoff M,Neisius U,Ikoma A,et al. Proteinase-activated receptor-2 mediates itch:a novel pathway for pruritus in human skin[J]. J Neurosci,2003,23(15):6176-6180.
4Steinhoff M,Vergnolle N,Young S H,et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism[J]. Nat Med,2000,6(2):151-158.
5Sun Jun,Dou Wei,Shen Hong,et al.Comparison of the effects of nifedipine,verapamil,and low-molecular-weight heparin on SLIGRL-NH2-induced calcium influx through proteinase-activated receptor 2 activation[J]. Pharmacology,2014,93(5-6):216-219.
6Shimada S G,Shimada K A,Collins J G. Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist,SLIGRL-NH2[J]. Eur J Pharmacol,2006,530(3):281-283.
7Jiao YuYan,Ubrich N,Marchand-Arvier M,et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits[J]. Circulation,2002,105(2):230-235.
8Song Y K,Kim C K. Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes[J]. Biomaterials,2006,27(2):271-280.
